Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
Study Details
Study Description
Brief Summary
This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Sepsis patients admitted in the Department of Critical Care Medicine, Zhongnan Hospital will be included.
There are three groups of patients in this study: control group, sepsis group and septic shock group.
The interleukin-37 (IL-37) concentration in urine was analyzed in the day 1, 2, 4, 6.
Additionally, IL-37 concentration between blood stream infection groups and non-infection groups were analyzed. IL-37 concentration between survivors and non-survivors were also compared. IL-37 concentration were followed from day 1, 2, 4, 6.The correlation between the concentration of IL-37, IL-1β, IL-6、IL-10 and TNF-α were analyzed. Furthermore, the investigators will determine the correlation between the concentration of IL-37, sepsis associated organ dysfunction, 28-day mortality. Lastly, the predictive value of IL-37 to sepsis associated organ dysfunction and prognosis were explored.
Study Design
Outcome Measures
Primary Outcome Measures
- 28-day all-cause mortality [28 day]
Number of patients who were confirmed to be dead within 28-day from enrollment onto the study
Secondary Outcome Measures
- ICU all-cause mortality [28 day]
Number of patients who were confirmed to be dead in ICU from enrollment onto the study
- ICU length of stay [28 day]
Length of intensive care unit stay
- Hospital length of stay [28day]
Length of hospital stay
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 years or older
-
Expected length of stay>24 hours in intensive care unit (ICU)
-
Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection
Exclusion Criteria:
-
anuria
-
ICU readmission in 28 days
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Zhongnan Hospital of Wuhan University | Wuhan | Hubei | China |
Sponsors and Collaborators
- Zhongnan Hospital
Investigators
- Study Chair: Dawei Wang, MD, Wuhan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Dawei Wang